Appreciation of trimetazidine treatment in experimental sepsis rat model

Basit Öğe Kaydı
dc.authoridCömert, Bilgin/0000-0002-2148-5356
dc.authoridinal, volkan/0000-0003-2649-104X
dc.authoridÖCAL, Ramazan/0000-0002-9172-9854
dc.authoridTanoglu, Alpaslan/0000-0002-7477-6640
dc.authorwosidCömert, Bilgin/P-3030-2019
dc.authorwosidinal, volkan/A-6069-2018
dc.authorwosidÖCAL, Ramazan/O-5832-2019
dc.authorwosidTanoglu, Alpaslan/AAI-5138-2020
dc.contributor.authorTanoglu, A.
dc.contributor.authorYamanel, L.
dc.contributor.authorInal, V
dc.contributor.authorOcal, R.
dc.contributor.authorComert, B.
dc.contributor.authorBilgi, C.
dc.date.accessioned2024-06-12T11:14:07Z
dc.date.available2024-06-12T11:14:07Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: Our aim was to determine the efficacy of trimetazidine on experimental sepsis rat model. Material and methods: Sixty rats were randomized into three groups. In Group 1, sepsis was induced. In Group 2, sepsis was induced and as a therapeutic agent trimetazidine was given. In Group 3, rats were sham operated. Serum interleukin-1 beta (IL-1 beta), tumor necrosis factor alfa (TNF-alpha), superoxide dismutase (SOD), glutathion peroxidase (GSH-Px) and malondialdehyde (MDA) levels were determined in all groups. Results: In Group 2, serum GSH-Px and SOD levels were statistically significantly higher than in Group 1 (p < 0.05) and serum MDA levels were statistically significantly lower than in group 1 (p < 0.05). Trimetazidine also significantly decreased the levels of IL-1 beta and TNF-alpha which are the proinflammatory cytokines (p < 0.05). Conclusion: Trimetazidine treatment significantly improved inflammation, oxidative stress and membrane destruction in LPS-induced sepsis. As the proinflammatory cytokines are supposed to play a primary role in the pathogenesis of sepsis, we assumed that the trimetazidine treatment would give new insights into the treatment of sepsis (Tab. 1, Fig. 5, Ref. 29). Text in PDF www.elis.sk.en_US
dc.identifier.doi10.4149/BLL_2015_024
dc.identifier.endpage127en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue2en_US
dc.identifier.pmid25665480en_US
dc.identifier.scopus2-s2.0-84923287438en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage124en_US
dc.identifier.urihttps://doi.org/10.4149/BLL_2015_024
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23789
dc.identifier.volume116en_US
dc.identifier.wosWOS:000350525800011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherComenius Univen_US
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSepsisen_US
dc.subjectTrimetazidineen_US
dc.subjectInflammationen_US
dc.subjectProinflammatory Cytokinesen_US
dc.subjectOxygen-Free-Radicalsen_US
dc.subjectLipid-Peroxidationen_US
dc.subjectSeptic Shocken_US
dc.subjectSurvivalen_US
dc.titleAppreciation of trimetazidine treatment in experimental sepsis rat modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu